Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIMZELX vs BYSANTI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.
Ig G1κ monoclonal antibody that binds to the neonatal Fc receptor (Fc Rn), reducing Fc Rn-mediated recycling of Ig G, thereby lowering circulating Ig G levels including pathogenic Ig G autoantibodies.
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,Active psoriatic arthritis in adults,Active ankylosing spondylitis in adults
FDA: Treatment of generalized myasthenia gravis (g MG) in adult patients who are anti-acetylcholine receptor (ACh R) antibody positive.,Off-label: Not indicated for other conditions.
Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.
Initial dose 2 mg subcutaneously twice daily; after 3 months, increase to 4 mg subcutaneously twice daily based on clinical response and tolerability.
Terminal elimination half-life is approximately 26 days (range 22–29 days) across approved doses; supports every 4-week subcutaneous dosing.
Terminal elimination half-life: 64-104 hours (mean 84 hours). Clinical context: Supports once-daily dosing; steady-state achieved in ~2-3 weeks.
Bimekizumab is likely degraded into small peptides and amino acids via general protein catabolism. It is not metabolized by CYP450 enzymes.
Degraded by general proteolysis into small peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Bimekizumab is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism; no renal or biliary excretion of intact antibody. Fecal excretion of degraded fragments is minor (<1%).
Biliary/fecal (55-65% as parent drug and metabolites); renal (30-40%, primarily as conjugated metabolites, <3% unchanged).
Approximately 99% bound to target (IL-17A and IL-17F) in serum; albumin binding is negligible.
>99% primarily to albumin.
Volume of distribution at steady state is approximately 7.0 L (0.1 L/kg assuming 70 kg), indicating limited extravascular distribution, consistent with a monoclonal antibody primarily in plasma and interstitial fluid.
Approximately 30 L/kg (0.43 L/kg in humans based on 70 kg). Extensive extravascular distribution, particularly to the liver (target organ via OATP1B1 uptake).
Subcutaneous: Approximately 80% (range 60–100%) compared to intravenous administration.
Oral: 20-30% (variable; low due to first-pass metabolism in gut wall and liver).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m2).
No dose adjustment recommended for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease; use not recommended.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use not recommended.
Safety and efficacy not established in pediatric patients.
Not approved for use in pediatric patients. Safety and efficacy not established.
No specific dose adjustment recommended; pharmacokinetics similar to younger adults in clinical studies with patients up to 75 years.
No specific dose adjustment required based on age. Use caution due to potential for decreased renal function and increased sensitivity to adverse effects; monitor closely.
None.
WARNING: Increased risk of serious infections, including opportunistic infections. Due to its mechanism of reducing Ig G levels, BYSANTI may increase the risk of infections. Monitor for signs and symptoms of infection and withhold treatment if severe infection occurs.
Increased risk of infections, including serious infections; avoid use during active infection,Hypersensitivity reactions including urticaria and angioedema,Exacerbation of inflammatory bowel disease (Crohn's disease or ulcerative colitis),Potential for increased suicidality or depression; monitor for neuropsychiatric symptoms,Avoid live vaccines during treatment,Tuberculosis screening prior to initiation
Serious infections: Increased risk of infections, including opportunistic infections. If severe infection occurs, withhold therapy.,Hypersensitivity reactions: Monitor for infusion-related reactions (e.g., pyrexia, headache, hypertension).,Immunizations: Avoid live or live-attenuated vaccines during treatment.,Fetal risk: May cause fetal harm based on animal studies; advise females of reproductive potential of potential risk.
Known hypersensitivity to bimekizumab or any excipient,Active tuberculosis or other severe infections
Hypersensitivity to efgartigimod alfa or any excipients.
There are no known food interactions with BIMZELX. Take with or without food.
No specific food interactions are known with BYSANTI. However, grapefruit and other CYP3A4-modulating foods may affect co-administered medications, but not bimekizumab itself. Maintain a balanced diet as recommended for overall health.
Bimekizumab is a humanized monoclonal Ig G1 antibody that inhibits IL-17A and IL-17F. As a large protein, it is transported across the placenta via Fc Rn-mediated transfer, with fetal levels increasing during the second and third trimesters. Available data are insufficient to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal studies showed no evidence of teratogenicity or fetal harm in monkeys at doses up to 100 mg/kg (approximately 30 times the human exposure at the recommended dose). However, monoclonal antibodies are known to cross the placenta, and the theoretical risk of fetal immune suppression exists. Therefore, bimekizumab should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
No human data; animal studies insufficient. Based on mechanism (CGRP receptor antagonist), theoretical risk of fetal harm; avoid use in pregnancy, especially first trimester.
It is unknown whether bimekizumab is excreted in human milk or absorbed systemically after ingestion. Monoclonal antibodies are generally present in breast milk at very low concentrations with limited oral bioavailability due to protein digestion in the infant's gastrointestinal tract. The M/P ratio has not been determined. Due to the potential for adverse reactions in the breastfed infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
No human data; present in animal milk. M/P ratio unknown. Not recommended during breastfeeding.
No dose adjustment is recommended during pregnancy based on pharmacokinetic changes. Bimekizumab clearance is not expected to be significantly altered by pregnancy-related physiological changes. However, given the limited data, the drug should be used only if clearly needed. Monitor clinical response and adjust dose if necessary (though no standard guidelines exist).
No established dose adjustments; contraindicated in pregnancy due to potential risk.
BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively inhibits both IL-17A and IL-17F. It is administered subcutaneously with a loading dose at weeks 0, 2, 4, then every 8 weeks. Monitor for exacerbations of inflammatory bowel disease (Crohn's or ulcerative colitis) as IL-17 inhibition can rarely trigger or worsen these conditions. Do not administer live vaccines during treatment. Consider tuberculosis screening prior to initiation.
BYSANTI (bimekizumab) is a humanized monoclonal Ig G1 antibody that inhibits both IL-17A and IL-17F. For plaque psoriasis, the recommended dose is 320 mg (two subcutaneous injections) at weeks 0, 4, 8, 12, and then every 8 weeks. Assess for tuberculosis prior to initiation; latent TB must be treated before starting therapy. Monitor for new onset or exacerbation of inflammatory bowel disease; discontinue if symptoms occur. Can be used with or without methotrexate for psoriatic arthritis. Live vaccines are contraindicated during treatment.
You may be at increased risk of infections, including upper respiratory tract infections and oral candidiasis. Report any signs of infection to your healthcare provider promptly.,If you have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis), tell your doctor before starting treatment, as this medicine can worsen it.,Do not receive live vaccines while on BIMZELX. Discuss any required vaccinations with your doctor before starting therapy.,This medication is given as an injection under the skin. You or your caregiver can be trained to administer it at home. Rotate injection sites and do not inject into tender, bruised, or scarred skin.,Store BIMZELX in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Keep in original carton until use.
BYSANTI is given as two injections under the skin, typically in the abdomen or thigh.,Tell your doctor if you have had tuberculosis or have been in close contact with someone with TB.,Do not receive live vaccines during treatment; non-live vaccines are acceptable.,Seek medical attention if you develop new or worsening stomach pain, diarrhea, or bloody stools.,Report any signs of infection (fever, chills, cough) as BYSANTI increases infection risk.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIMZELX vs BYSANTI, answered by our medical review team.
BIMZELX is a Prostaglandin Analog that works by BIMZELX (bimekizumab) is a humanized monoclonal Ig G1 antibody that selectively neutralizes interleukin-17A (IL-17A) and interleukin-17F (IL-17F), inhibiting their binding to the IL-17 receptor and subsequent pro-inflammatory signaling.. BYSANTI is a Prostaglandin Analog (Ophthalmic) that works by Ig G1κ monoclonal antibody that binds to the neonatal Fc receptor (Fc Rn), reducing Fc Rn-mediated recycling of Ig G, thereby lowering circulating Ig G levels including pathogenic Ig G autoantibodies.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIMZELX and BYSANTI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIMZELX is: Subcutaneous injection: 160 mg (two 80 mg injections) at week 0, week 2, week 4, then every 4 weeks.. The standard adult dose of BYSANTI is: Initial dose 2 mg subcutaneously twice daily; after 3 months, increase to 4 mg subcutaneously twice daily based on clinical response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIMZELX and BYSANTI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIMZELX is classified as Category C. Bimekizumab is a humanized monoclonal IgG1 antibody that inhibits IL-17A and IL-17F. As a large protein, it is transported across the placenta via FcRn-mediated transfer, with feta. BYSANTI is classified as Category C. No human data; animal studies insufficient. Based on mechanism (CGRP receptor antagonist), theoretical risk of fetal harm; avoid use in pregnancy, especially first trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.